Vernalis &r&d) Ltd.

Les Laboratoires Servier

Vernalis Limited

Alba Macias

Christopher John Graham

Paul Brough

Terance Hart

Steven Walls

Rachel Parsons

Stephen Roughley

Olivier Geneste

James Brooke Murray

András Kotschy

Árpád Kiss

Elodie Lewkowicz

Balázs Molnár

Csaba Wéber

Attila Vasas

Maïa Chanrion

Didier Demarles

Lisa Ivanschitz

Csaba Weber

Maia Chanrion

Arpad Kiss

Balazs Molnar

Mäia Chanrion

Ágnes Strofek

Vilibald Kun

Christopher Graham

Terrence Hart

Compounds of formula (I): wherein R, R, R, B, W, Z, m and n are as defined in the description.

Substituted piperidines as inhibitors of ubiquitin specific protease 7

Compounds of formula (I): wherein R, R, R, n and W are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring pro-apoptotic and/or anti-proliferative agents.

Substituted piperidines for the treatment of cancer

Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Aris optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Aris optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Aris a divalent radical selected from optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms.

Azetidine derivatives

Compounds of formula (I): wherein R, R, J, K, L, n and W are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring pro-apoptotic and/or anti-proliferative agents.

(Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them

Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Wherein Aris optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Aris optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Aris a divalent radical selected from the group consisting of optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms.

Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Formula (I) Wherein Aris optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Aris optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Aris a divalent radical selected from the group consisting of optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms. 

Azetidine derivatives as FAAH inhibitors

Growing community of inventors

Cambridgeshire, United Kingdom

Alba Macias